Follow-The-Filings

Security · featured owners

SUPN

Supernus Pharmaceuticals, Inc. COM Equity as of 2026 Q2 among managers we track

  • 2 Owners
  • Max 5.0%
  • $20M
  • 1 exit

Who owns this now

Largest portfolio weights among featured holders · max 5.0% (Michael Krensavage - Kren...) · not free-float ownership

  1. Michael Krensavage 5.0%
  2. Third Avenue Management 1.1%

holders

sorted by % of portfolio · long equity only · exits show last held size · open a manager for their book

history
Michael Krensavage - Krensavage Asset Management 2026 Q2 5.0% Hold 280,681 $13M hist
Third Avenue Management 2026 Q2 1.1% Hold 152,724 $7M hist
Farallon Capital Management exited 2026 Q2 last 2026 Q1 0% Exit 0.00 pp 4,000 $207K hist

2 current · 1 exited last period · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2024 FY2025
Revenue $661.82M $718.95M
Gross profit * $583.91M $644.39M
Gross margin * 88.2% 89.6%
Net income $73.86M -$38.55M
Net margin * 11.2% -5.4%

Balance sheet

Metric FY2024 FY2025
Total current assets $686.07M $644.18M
Total non-current assets * $682M $808.47M
Total assets $1.37B $1.45B
Total current liabilities $292.4M $338.17M
Total non-current liabilities * $39.94M $52.76M
Total equity $1.04B $1.06B

Cash flow

Metric FY2024 FY2025
Cash from operations $171.95M $47.33M
Cash from investing -$189.87M $4.11M
Cash from financing $12.19M $9.13M
Net change in cash -$5.72M $60.57M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders